Workshop with Susanna Finlay
Susanna Finlay's research interest include the social impacts of Synthetic Biology.
During the workshops we have looked at study cases and discussed the impact of science on society.
We considered the following issues:
- where the scientists/engineer's responsibilities end?
- should scientists think about their impact when doing research?
For more information, have a look at this website.
Ethical panel with Claire Marris
"iGEM team helps prevent rogue use of synthetic biology"
Virginia Bioinformatics Institute (VBI) at Virginia Tech is working on indetifying pracitical solutions to implement legal reuglations on the commericla distribution of GMOs or DNA sequences.
Algorithms under development assess how similar a specific DNA sequence is to entries in the Centers for Disease Control and Prevention’s Select Agent and Toxin List. Keyword lists help to track down matches and allow for continual fine-tuning of the effectiveness of each search. The students are compiling a database of test cases that allows them to estimate the performance of different screening strategies.
Refrence: Article contains further links to articles on Ethical issues with SynBio iGEM team helps prevent rogue use of synthetic biology
Human Practices Report
The Imperial iGEM project focuses on the design of a system that gives a rapid response, because we noticed that many previous biosensor projects had only achieved relatively slow responses to a stimulus. Our concept is an adaptable, modular and robust fast response system, which is fundamental for modern applications in synthetic biology.
One possible application for this fast response module is in the detection of water-borne parasites. We realised that synthetic biology is rarely used in the fight against neglected tropical diseases (NTDs), and we wanted to be pioneers in this field.
Over 1 billion people - a sixth of the world’s population - suffer from one or more NTD (WHO, 2007). Despite affecting over 90% of the world’s population in one way or another, only 10% of worldwide health research funding goes into finding preventative or curative treatment for NTDs. This statistic was published by the Global Health Forum and is now referred to as the ‘10/90 gap’ (Global Forum for Health Research, 1999). The 10/90 gap probably exists because of the fact that the majority of people affected by NTDs live in developing countries, and so profit margins for NTD drugs are negligible.
NTDs are most commonly found in sub-Saharan Africa and in urban settings in developing countries in Asia and Latin America (Hotez et al, 2006). The effects of NTDs include long-term disability, disfigurement, impaired childhood growth, adverse pregnancy outcomes and reduced economic productivity. In fact, the effect on worker productivity causes billions of dollars to be lost each year, and retains a country in poverty (Hotez et al, 2006; Molyneux et al, 2005). Added to the problem is that of climate change, which is creating favourable conditions for the spread of many NTDs and their vectors, and so it is expected that in the years to come their effects will be felt all the more gravely.
Schistosomiasis, also known as bilharzia, is an NTD that affects over 200 million people worldwide (Steinmann et al, 2005) and has drastic effects on the economic viability of the country in which it is endemic (Sturrock, R. F., 1993). The schistosoma species which are human parasites are found in sub-Saharan Africa, Latin America and South-East Asia (Liu et al, 2010). The parasite has a complicated lifecycle, involving two hosts; snails and humans, and infects humans by breaking through the skin during contact with contaminated water.
In recent years, the treatment of schistosomiasis, especially among schoolchildren, has improved markedly due to the availability of praziquantel for generic production. This drug is effective as a single dose, can be administered by primary healthcare teams and directly affects the schistosoma parasite. Nevertheless, the parasite is still a major problem.
At present, most of the detection of schistosoma is only possible after it has infected the human host. There are two main types of diagnosis; antibody detection in blood serum, or egg detection in urine and stool samples (Liu et al, 2010; Shazley & Saadany, 2006). The latter is more commonly used but it is a lengthy and uneconcomical technique. The detection of schistosoma in the local environment is done rarely, as it is time-consuming and can require cumbersome equipment. Another drawback is the low sensitivity of the tests.
The infective form of schistosoma, called a cercaria, secretes proteases upon detection of human skin lipids (McKerrow & Salter, 2002). These proteases enable the cercariae to break through the skin barrier and infect the host.
We intend to use these proteases to detect the cercariae, because they can trigger a synthetic signalling pathway in our bacterium.
We have discussed a wide range of ethical, legal and social implications (ELSIs) of our project in both a Human Practices Workshop and an interdisciplinary Human Practices Panel Discussion, which involved synthetic biologists, social scientists and bioartists. The panel had some very useful suggestions which we addressed in our design.
As with any scientific development, there is always the potential for misuse. We have debated who we think should have access to methods used in synthetic biology. However, using it in its current state, the technology requires huge amounts of expertise, which is only possessed by research institutions and some commercial companies. Nevertheless, it has been proposed that some military organisations may possess sufficient resources to be capable of manipulating some developments for potentially detrimental ends. As synthetic biology develops as a field, the ease with which systems are put together and the level of automation will improve, and thus entry barriers will diminish. Technology will become more affordable, especially as there is an ‘open source’ ethos within the field of synthetic biology (this will be further discussed in ‘Legal Factors’ and 'Political Factors and Regulation', where we propose an independent, international governing body for synthetic biology).
Biosafety and Environmental risks
Of particular concern is the uncontrolled release of Genetically Modified Organisms (GMOs), either intentional or accidental, into the environment. The prospect of contaminating groundwater is particularly alarming in locations where coordination of water treatment is under-developed, as might be the case in some developing countries. We have considered how uncontrolled release would affect the local environment, and the biodiversity of its ecosystem. This led us to opt f for a chassis that was already endemic in most environments. Our choice of chassis was B. subtilis, which is a bacterium that is often found in soil and is non-pathogenic.
To make the detection module we will integrate the required genes as two separate pieces of DNA (cassettes) directly into B.subtilis genome. In order to limit the lifetime of the bacterium in the environment, we will integrate the cassettes at areas in the genome such that they will interfere with essential genes, such as those that are needed to make an essential amino acid, called tryptophan, and pyrimidines, which are required for DNA synthesis. As a result, the final version of our product would only be able to survive in special conditions where these additional nutrients are provided. Therefore, if it were to be released into the environment, it would in theory only survive for a limited period of time (this would be tested experimentally to quantify the exact lifetime of the bacterium in different environments and conditions).
Most techniques of introducing new genes into organisms require additional selection genes, these usually confer resistance to a particular antibiotic such as spectinomycin. Our design will also include these genes, however an additional Dif sequence built into our design will ensure that these genes are quickly removed from the bacteriuml, using an inherent control mechanism. As a result, the bacteria used in our final product will not be antibiotic resistant. Integration direclty into the genome also ensures that the detection module genes will remain in the organism long enough for the kit to be used effectively.
An additional level of confidence is that a component of the reaction mixture, called catechol, actually kills the bacteria a few hours after it is added. Nevertheless, we are aware that in order for this to occur, the catechol must be added appropriately, and this relies on the correct use of the detection kit. However, if the bacteria were released into the environment without being exposed to catechol, the original genome disruption would be sufficient to ensure that the bacteria would not survive.
We recognise that biological systems are inherently unpredictable and have the capacity to change. Nevertheless, we believe that the benefits of controlling the population and spread of schistosoma makes this an important project to pursue on the proviso that biosafety issues and environmental impacts are closely monitored, controlled and managed. We advocate continued, regular testing of the bacteria in order to ensure that any mutations, which would result in the deviation from its function, are noticed early and so the problem can be remediated. We would ensure that there are thorough, controlled and longitudinal studies of the effects of the bacteria on a range of environments and seasons, prior to the marketing of the product.
Political factors and regulation
Regulation of the use of synthetic biology is a huge concern of both synthetic biologists and the wider public. We have debated whether regulation should be external or internal, and government-led or –funded. Self-regulation could be an effective way of ensuring that rules are adhered to, but with a lack of external scrutiny, it is unlikely to be sufficient for the public to feel entirely confident about the issues raised. This is due to the difficulty in keeping track of such a diffuse network of researchers (Schmidt, 2008) and the fact there is always the potential for people to ignore the rules. We therefore believe that an international, independent body should monitor organisations working in the field of synthetic biology, and that there should be transparency in all their dealings.
We wanted to know what control measures were in place at our university and whether or not the government plays a role in this. At Imperial College London, the GM safety committee is responsible for ensuring that all research adheres to the regulations set down by the Health and Safety Executive (HSE). The first stage in the commencement of a project is the completion of a comprehensive risk assessment, which is submitted to the GM safety committee, which will then (i) approve the risk assessment and (ii) identify control measures. These control measures then need to be put in place. If the GM classification is Class 2 or higher, the project must be discussed with the Director of Occupational Health to determine whether health surveillance is necessary.
A legal framework to control the use and ownership of the developments of synthetic biology is essential in order to establish the open source philosophy. We are aware that copyrights and patents can limit the scope of further research, because information is not accessible or research centres must pay heavily to use such innovations. There are many arguments for the implementation of open source synthetic biology, as opposed to using patenting laws. It has been suggested that open source projects drive innovation within the field, but they can also present huge logistical problems in terms of regulation upon diffusion of the technology (Schmidt, 2008).
There has been extensive media coverage concerning access to medicines and technology in the fight against NTDs. In the majority of cases, strong intellectual property rights (IPR) regulations rule out the generic production of drugs so that no alternative to costly medicines are available. The majority of NTDs occur in developing countries, where healthcare provision is often poor and there are few resources available in terms of NTD medication. Strong IPR regulations for NTD drugs are often seen as unnecessary because pharmaceutical companies will not generate profits because people who can afford the drugs do not need them, and vice versa. Wider access to NTD drugs could be achieved by ensuring that research is available through open source.
We have ensured that the cost of production of the detection kit is low enough to make it affordable to the people who need it. This was achieved by designing a product that is economical to manufacture and uses inexpensive chemicals in the process.
The role of industry in synthetic biology is a controversial one. Industry is driven by profit, and we would like to ensure that no company has a monopoly in any particular area through the ownership of one or more of our modules. Ideally, we would like the technology to be available for generic produces to manufacture.
In particular, universities are centres of learning, and are not profit-generating businesses. We therefore believe that it is essential that research done at universities is accessible and can be used to benefit others. This could be achieved by making the modules available through open source, or by licensing the modules to different companies so that no one company has a monopoly.
It is very important to us that the communities who would benefit from the detection kits have access to them and so they must be affordable and available in appropriate locations. Accessibility to the detection kits would depend on the following factors:
- Distribution & ease of transportation
- Shelf life
- Ease of use
- Social acceptability
We also considered the type of organisation who would distribute the detection kits. This could be done by government organisations and local authorities, which would be an ideal solution because it would allow developing countries to organise and manage their local distribution and use of the kits, or use existing infrastructure if it is already in place. However, this may not be the best option if government resources are poor or if there is a threat of corruption or discrimination. If this were the case, aid programs and NGOs may be in a better position to distribute the kits.
We do not believe that our detection kit on its own can solve the problem of schistosoma. Improved sanitation and education is needed in combination with the environmental control of parasites. It would be necessary to carry out an assessment of the level of education regarding parasitic infections, in particular schistosomiasis, in order to determine where further education was needed. This education programme could be given alongside the training in the use of the detection kit to ensure the long-term feasibility of our project, and also to overcome any cultural boundaries there may be.
It is also essential that we determine the social acceptability of the kits before we finalise the design. During this process, it is possible that we would find that different designs are more appropriate in different settings, and the overall design may be needed to be tailored to a specific community, depending on the setting in which it is implemented.
The benefits to local communities are unlikely to be seen straight away. This is due to the nature of NTDs and their prolonged effects on individuals, and the fact that much of the problem with them is due to socio-economic factors (Hotez et al, 2006; Molyneux et al, 2005). However, as the incidence of, for example, schistosomiasis decreases, the economic productivity of a particular population will hopefully improve, and this should result in a positive feedback loop where the NTD incidence decreases even further due to the improved economy of the given community.
Due to the constraints imposed by the environment in which most NTDs occur, our detection kit needs to be portable to resource-poor settings, affordable, easy to use and store, and not dangerous if released into the environment.
We considered the benefits of targeting the detection kit for use by organisations instead of domestic use. One advantage is that training in the use of the kit would only need to be given to employees of the organisations, and not to whole communities, thus making the system much more viable in terms of cost and time. Also, disposal of the kits after use was too great an issue in terms of infrastructure. We therefore decided to target it for use by local authorities so that water can be tested in different regions.
Our project involves taking genes from a pathogenic bacterium, Streptococcus pneumoniae, which is by no means ideal. However, an alternative could not be found in a non-pathogenic species. These genes are only involved in the competence pathway and not in any pathways that may confer pathogenicity. There are also homologous genes found in non-pathogenic bacteria. Therefore, we do not expect any adverse consequences from using these genes out of context, and we would ensure that testing is done prior to the marketing of our product so that it is certain that no pathogenicity is transferred to our bacterium.
Our choice of chassis is B. subtilis, a non-pathogenic bacterium that is present in many environments, such as soil. Using B. subtilis means that the cells can be transported in spore form, allowing them to withstand large temperature extremes. This means that the whole kit will be easy to store and transport, and so will be straightforward to use in resource-poor settings. Before use, the spores would need to be germinated, but this represents no great problem.
Another advantage of using B. subtilis is that we can remove antibiotic resistance genes using Dif sequences, so the final synthetic organism will not be resistant to antibiotics. These antibiotic resistance genes are essential for selection during cloning. During the assembly of our constructs, we used two different antibiotics to select for cells that contained plasmids that contained either the spectinomycin or chloramphenicol resistance genes. Either side of these resistance gene casettes are Dif sites. When the constructs are integrated into the B. subtilis genome, they are relatively stable and cannot be lost, so the resistance genes are no longer needed. At this time, the Dif sites are targeted by an inherent enzyme which all B. subtilis cell possess, namely a recombinase. This recombinase removes the stretch of DNA between each Dif site, including the antibiotic resistance genes.
We considered different types of output, such as an odour or light. However, the most reliable and the fastest way of getting a response appeared to be by using the C2,3O reaction, which has a colour output. Our only concern about this is that when testing water with a high level of sediment, it may be hard to observe the colour change, which is yellow-orange. If this were the case, an odor might be a possible output.
The design of the final product would depend on whether it is more appropriate to test a fixed volume of water using a container, or to use a dipstick to test a variable amount of water. The latter technique would allow one to increase the sensitivity of the test by attracting cercariae using certain lipids, which could be released by the kit. This would lead to the establishment of a concentration gradient of lipids, leading to a higher number of cercaria to be detected.
We intend the test to be quantitative, but this would require a spectrophotometer. However, we have looked at ways to implement quantification by eye, much like a pH indicator test.
Due to the modular design of the detection kit, there are many other applications that would benefit from a fast response module. There are also many other parasites that could potentially be detected, especially those that use proteases to infect their host, such as hookworm, guinea worm and strongyloides. These could be other potential applications of our system.
Questions from the Human Practices Panel
- Why would detecting schistosoma be useful?
In deprived rural communities, where resources are limited and healthcare provision is poor, a detection system for parasites could allow the treatment of water systems by using simple, harmless chemicals. It might also increase awareness of the presence of the parasite, and so people in the surrounding areas can be advised to let the water stand for 24 hours before use (in which time the cercariae will die) or to use an alternative source of water, if possible.
Epidemiological studies of NTDs are necessary to ascertain the efficacy of disease prevention and treatment. Disease mapping allows the analysis of, for example, the impact of climate change on vector-borne diseases throught the use of virtual mapping applications such as Google Earth. The Infectious Disease Epidemiology Department at Imperial College London have established www.spatialepidemiology.net; one of several websites where geospatial health is being established as an essential factor in the study of disease.
One advantage of disease mapping is that it allows more effective intervention at the local level. In addition to this, environmental components are considered in relation to morbidity, so that models can be built to offer more accurate predictions of how a disease can behave on a global scale.
CONTRAST, a network of researchers across sub-Saharan Africa, carries out schistosomiasis risk mapping and prediction. Of particular interest is the transmission of the disease and host-parasite dynamics.
- What is currently being used to detect schistosoma in water?
The systems currently in use for detecting schistosoma in the field are often expensive, time-consuming and are relatively insensitive. They are therefore unsuitable for use in the field. Some examples include filtration and RT-PCR. It is much easier to detect the parasite after it has infected a human, by testing stool or urinary samples with microscopy or bloody with an antibody test.
- What are the chances of the schistosoma protease genes mutating, resulting in different proteases which our system can no longer detect?
This is very unlikely, because the proteases are vital for the entry of the cercariae into the human body. If the specificity of these changed, they would not be able to invade the body and as a consequence, the cercariae would die within 24 hours.
- Why not just improve sanitation?
While this would be an ideal solution, it represents a significant logistical problem, especially in rural settings. Among the 8 Millenium Development Goals for 2015 set out by WHO, basic sanitation features as a key factor in the fight to combat extreme poverty. The target is that by 2015, only 23% of the population will be living without improved sanitation. However, at the current rate of progress, the projected figure for 2015 is currently 36%, meaning that an extra 1 billion people who should benefit from the MDGs will miss out (WHO/UNICEF, 2010). This shortfall in the number of people who have access to improved sanitation is mostly due to poor infrastructure, lack of sustainability and ineffective financial aid. Therefore, we propose that a combination of approaches is needed to compliment the use of the detection kit. This could include enhanced sanitation and improved access to essential medicines and education where needed.
- Why do we need a fast response?
For synthetic biology to be of real use in this age, and in applications such as parasite detection, it is fundamental that we get a fast response. Nowadays people expect results quickly, and the wider public could easily not notice the potential that synthetic biology has if the results were not seen on a fast enough timescale. NTDs are most prevalent in remote settings, where resources are limited and vast areas of land are needed to be tested as quickly as possible. Therefore, a quick output would facilitate a greater frequency of testing.
C2,3O Catechol 2,3 Dioxygenase;
ELSI Ethical, legal and social implications;
FDI Foreign direct investment;
GMO Genetically modified organism;
HSE Health and Safety Executive;
IPR Intellectual property rights;
MDG Millennium development goals;
NTD Neglected tropical disease;
R & D Research and development;
WHO World Health Organisation;
Adair R, Nwaneri O. (1999) Communicable disease in African immigrants in Minneapolis. Arch Intern Med; 159: 83-85
Balmer, A. & Martin, P. (2008) Synthetic Biology: Social and Ethical Challenges www.syntheticbiology.org Accessed on 05/08/10
Check, E. (2002) ‘Venter aims for maximum impact with minimal genome,’ Nature Vol. 420 (28th November): 350 Nature Editorial (2008) ‘Pathways to Security,’ Nature Vol. 445 (25 Sept): 43
David, R.C. (2005) Schistosomiasis: overview of the history, biology, clinicopathology, and laboratory diagnosis, Clin. Microbiol. Newsl. 27 pp. 163–169
D. Engels, E. Sinzinkayo and B. Gryseels, Day-to-day egg count fluctuation in Schistosoma mansoni infection and its operational implications, Am. J. Trop. Med. Hyg. 54 (1996), pp. 319–324
Global Forum for Health Research (1999) 10/90 Report on Health Research 1999
Gryseels, B., Polman, K., Clerinx, J. & Kestens, L. (2006) Human schistosomiasis, Lancet 36, pp. 1106–1118
Hotez, P. J., Ottesen, E., Fenwick, A., & Molyneux, D. H. (2006) The neglected tropical diseases: The ancient afflictions of stigma and poverty and the prospects for their integrated control and elimination. Hot topics in infection and immunity in children III. New York: Kluwer Academic/Plenum Publishers.
Johnson, B. (2010) Synthetic Biology Dialogue Molyneux, D. H, Hotez, P. J. & Fenwick, A. (2005) Rapid-Impact Interventions: How a Policy of Integrated Control for Africa’s Neglected Tropical Diseases Could Benefit the Poor PLoS Medicine.
Liu, Z. S., Zhang, L., Yang, H., Zhu, Y. H., Jin, W., Song, Q. A. & Yang, X. L. (2010) Magnetic microbead-based enzyme-linked immunoassay for detection of Schistosoma japonicum antibody in human serum. Analytical Biochemistry 404:127-134
McKerrow, J. H. & Salter, J. (2002) Invasion of skin by Schistosoma cercariae. Trends in Parasitology 18:193-195
Roca C, Balanzo X, Gascon J, Fernandez-Roure JL, Vinuesa T, Valls ME, Sauca G, Corachan M. Comparative, clinicoepidemiologic study of Schistosoma mansoni infections in travellers and immigrants in Spain. Eur J Clin Microbiol Infect Dis 2002; 21: 219-223
Schmidt, M. (2008) Diffusion of synthetic biology: a challenge to biosafety Syst Synt Biol www.synbiosafe.eu accessed on 16/08/10
El Shazly, S. & El Saadany, S. (2006) Schistosomiasis Tanta Med. Sci. J. 1 pp. 1–10.
Steinmann, P.,Keiser, J., Bos, R., Tanner, M. & Utzinger, J. (2005) Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk, Lancet Infect. Dis. 6 pp. 411–425
Stothard, J. R. (2008) Improving control of African schistosomiasis: towards effective use of rapid diagnostic tests within an appropriate disease surveillance model. Transactions of the Royal Society of Tropical Medicine and Hygiene.
Sturrock, R. F. (1993) The control of schistosomiasis. Second report of the WHO expert committee Geneva: World Health Organisation Vol II
World Health Organisation (2003) Communicable diseases 2002: global defence against the infectious disease threat (ed. Kindhauser, M. K.), Geneva, pp. 106-107.
WHO/UNICEF (2010) Progress on sanitation and drinking-water 2010 update
http://www.who.int/schistosomiasis/en/ accessed on 14/08/10
WHO (2007) Manuscript of Neglected Tropical Diseases Annual Report 2006
Meeting with Professor Alan Fenwick and Dr Wendy Harrison of the Schistosomiasis Control Initiative (SCI)
The SCI is based at the St Mary's Campus of Imperial College London and carries out research into NTDs, working with countries in sub-Saharan Africa to establish various disease control programmes.
The meeting was both informative and constructive, allowing us to shape our system so that it can be as useful as possible in a real world application.
We discussed the sensitivity of our system, which would be a key issue in the development and implementation of the detection kit. It was suggested that sampling issues could be our biggest problem, because there are various factors that affect the population of cercariae in particular volume of water. In addition to this, the lifetime of a cercaria is only around 24 hours, so any testing would need to be adapted so that it is statistically significant.
We decided that using skin lipids, such as linoleic and linolenic acid, to attract cercariae to the testing device may be useful in terms of increasing the signal. It may also be possible to use a dipstick instead of using a fixed volume of water to test. This would mean that the test would take a longer time, but it would enable the detection of cercariae at much lower population densities.
Dr Harrison suggested that we could use a visually quantify the amount of cercariae present, for example by using a colour gradient similar to a pH indicator test.
It was suggested that the sediment in the water may prevent one from seeing the colour change. However, we explained the modularity of our project, and how we could easily use a different output, such as smell.
When discussing the possible uses for our detection kit, we found that organisations such as the CONTRAST project, which does disease risk mapping in sub-Saharan Africa, could find our project very useful indeed.
It may also be useful to have a test that distinguished between different Schistosoma species. This could be done if the proteases released by each species had a slightly different amino acid recognition motif, which would define our linker sequence between the AIP and cell surface protein.
We also wanted to know what Professor Fenwick and Dr Harrison's opinion were on praziquantel resistance. In fact, resistance has not been observed. However, a certain amount of tolerance to the drug has been observed. This occurs when a certain Schistosome is able to survive in the body after the drug has been administered. However, a higher dosage will easily kill the parasite and prevent the tolerant strain from spreading.
Administration of praziquantel is not intended to reduce the transmission of schistosomiasis. Instead, it is hoped that by treating communities, the morbidity of the disease will decrease.
It was noted that detection of the miracidia in stool would be a much more useful way to detect the parasite, because it would indicate whether or not a given community needs to be treated with praziquantel.
We wanted to know if there were any other proteases that we might want to detect, in terms of NTDs. There is a protease which is released by Trypanosoma in the blood which could be used to diagnose Chagas disease. Currently, diagnosis of Chagas disease requires a lumbar puncture, which is hard to accomplish in resource-poor settings.